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METHODS OF MANUFACTURING
BIOACTIVE GELS FROM
EXTRACELLULAR MATRIX MATERIAL
CROSS REFERENCE TO RELATED
APPLICATIONS
This application is a continuation application of a co-
pending U.S. application Ser. No. 14/969,800, filed on Dec.
15, 2015, which is a continuation application of U.S. appli-
cation Ser. No. 14/811,993, filed on Jul. 29, 2015, now
granted U.S. Pat. No. 9,238,091, issued on Jan. 19, 2016
which is a continuation application of U.S. application Ser.
No. 14/332,465, filed Jul. 16, 2014, now granted U.S. Pat.
No. 9,119,831, issued on Sep. 1, 2015, which is a continu-
ation application of U.S. application Ser. No. 14/174,980,
filed Feb. 7, 2014, now granted U.S. Pat. No. 8,802,436,
issued on Aug. 12, 2014, which claims priority to and benefit
of U.S. Provisional Application No. 61/762,437, filed Feb. 8,
2013, the entire content of each is incorporated by reference
herein for all purposes.
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TECHNICAL FIELD OF THE INVENTION
The present invention is related to methods of manufac-
turing bioactive gels from extracellular matrix material and
their uses for restoration of tissues in a patient.
BACKGROUND
Biologic scaffolds composed of extracellular matrix mate-
rial (ECM) have been used for the repair of variety of tissues
including the lower urinary tract, esophagus, myocardium
and musculotendinous tissues, often leading to tissue-spe-
cific constructive remodeling with minimal or no scar tissue
formation.
Although uses of ECM as scaffolds for preclinical and
clinical tissue engineering and regenerative medicine
approaches to tissue reconstruction are very promising,
challenges remain in the process to manufacture bioactive
gels from ECM, which retain their bioactivity.
The methods of manufacturing bioactive gels from ECM
described in the prior art require the use of enzymes and are
time consuming because they require aggressive purification
steps, which may lead to depletion in the bioactivity of the
gels and may present additional regulatory barriers to mar-
keting.
Thus, a need exists to manufacture bioactive gels from
ECM which avoids cumbersome preparation and purifica-
tion steps yet result in gels that retain the bioactivity of the
original material.
SUMMARY OF THE INVENTION
The present invention generally pertains to improved
methods of manufacturing bioactive gels from ECM which
retain sufficient bioactivity to positively assist in tissue
repair. The present invention utilizes reagents that do not
introduce additional regulatory burdens for market approval
or clearance of the gel invention. Thus, the invention
describes methods of manufacturing bioactive gels from an
2
ECM comprising (a) providing the ECM from one or more
of the group consisting of but not limited to small intestine
submucosa (SIS), urinary bladder submucosa (UBS), uri-
nary bladder matrix (UBM) (includes epithelial basement
5 membrane), porcine dermis (PD), and liver basement mem-
brane (LBM), (b) particularizing the ECM to a particle size
in the range of about I µm to about 1000 µm, (c) solubilizing
concentrations in the range, of about 0.5 to 11% weight/
volume (w/v) of particularized powder in sodium hydroxide
10 (NaOH) in the range of 0.1 to 1.0 M for periods of time
ranging from about I hour to about 48 hours at 4° C., (d)
neutralizing the solubilized ECM prepared in step (c) with
hydrochloric acid (HCl), optionally equimolar relative to
NaOH, ranging from 0.1 to I M to form the gel, and (e)
15 optionally, freezing the neutralized solubilized ECM pre-
pared in step (d), optionally (f) lyophilizing the frozen ECM
prepared in step (e), and optionally (f) reconstituting the
lyophilized gel in water or saline.
The advantages provided by the methods of manufactur-
20 ing bioactive gels in the above manner are that aggressive
purification steps, which are deleterious to bioactivity,
tedious to perform or are time consuming, and which
increase the regulatory burden (e.g. FDA approval), are
avoided.
25
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the FGF-2 content (pg/mg) of gels follow-
ing various solubilization conditions in NaOH according to
30 embodiments of the invention. All gels not marked with a %
w/v were done at 7.0% w/v UBM to NaOH. All gels in FIG.
1 were done at 7.0% w/v UBM to NaOH.
FIG. 2 shows the VEGF content (pg/mg) of gels following
various solubilization conditions in NaOH according to
35 embodiments of the invention. All gels not marked with a %
w/v were done at 7.0% w/v UBM to NaOH. All gels in FIG.
1 were done at 7.0% w/v UBM to NaOH.
DETAIL DESCRIPTION
40
The present invention is directed to methods of manufac-
turing bioactive gels from ECM, i.e., gels which retain
sufficient bioactivity to positively assist tissue repair by
decreasing the time needed for repair, decreasing scar tissue
45 formation, and improving restoration of the injured tissue to
its pre-damaged native structure and function as compared
to injured tissues not treated with the bioactive gel according
to the invention. The gel invention and methods of making
described herein serves as scaffolds for preclinical and
50 clinical tissue engineering and regenerative medicine
approaches to tissue reconstruction. Bioactivity in the ECM
gel according to the invention is in the range of about 0 to
100%, 25-75%, 10-25%, less than 10%, less than 5% or less
than 1% of the bioactivity of one or more bioactive mol-
55 ecules in the native from which the gel was derived. As will
be described in detail below, these manufacturing methods
take advantage of a new recognition that bioactive gels from
ECM can be created by solubilizing a particularized ECM in
a basic (greater than pH 7) environment, which when
6o neutralized with acid provides bioactive gels.
In accordance with the inventive methods, the ECM may
be derived from layers of native mammalian tissues includ-
ing but not limited to submucosa, dermis, epithelial base-
ment membrane, or from tissues such as aponeurosis, fascia,
65 tendon, ligament, smooth and skeletal muscle and treatment
site-specific ECM. The native mammalian tissue source may
be porcine, bovine, ovine, allogenic, or autogenic, for
US 9,795,713 B2
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example. For example, the ECM may be SIS (small intes-
tinal submucosa), UBS (urinary bladder submucosa) or
UBM (urinary bladder matrix) or liver basement membrane
(LBM) described in U.S. Pat. No. 6,576,265, U.S. Pat. No.
6,579,538, U.S. Pat. No. 5,573,784, U.S. Pat. No. 5,554,389,
U.S. Pat. No. 4,956,178, and U.S. Pat. No. 4,902,508, each
of which are incorporated by reference herein. In one
embodiment of the invention, the ECM is derived from a
mammalian tissue and comprises bioactive components of
the extracellular matrix material that are arranged and in
quantities similar to those in the tissue in its native form.
In accordance with the inventive method, the ECM
derived from any one of the above sources is particularized,
i.e., the size of the ECM particles are in a range of about 1
µm to about 1000 µm. In one embodiment, particularization
of the ECM prior to subjecting the ECM to a basic envi-
ronment provides homogeneity to the ECM, i.e., provides a
more uniform composition in comparison to ECM from
individual animals, decreasing the impact of inter donor
variability. In another embodiment, the particularization of
the ECM facilitates in solubilizing the matrix in a basic
environment by increasing surface area to volume ratio.
The particulate ECM product, e.g., particularized ECM, is
manufactured by grinding/milling or otherwise performing a
size reduction process to ECM typically but not exclusively
originally provided in sheet form. The resulting particulate
can be any desired range of density for example in the range
of about 0.1 g/cm3-10 g/cm3, about 0.10.1 g/cm3-1 g/cm3 or
about 1 g/cm3, and particle size for example in the range of
about 1 micron-1000 microns, about 200-700 microns,
about 300-600 microns, or about 400 microns.
A basic environment is provided by solutions of alkaline
compounds. Alkaline compounds which could be used in
accordance with the invention are metal hydroxides which
include, but are not limited to, LiOH, NaOH, KOH, RbOH,
and CsOH. Alkaline compounds which could be used in
accordance with the invention also include weak bases, such
as but not limited to, ammonia (NH3), pyridine (CsHsN),
hydroxylamine (HzNOH), methylamine (NH2CH3) and the
like. Alkaline compounds are generally used at a concen-
tration ranging from 0.1 Molar to 1.0 Molar, although
concentrations lower that 0.1 Molar or higher than 1.0 Molar
are also contemplated in an embodiment of the invention.
Concentrations of particularized ECM to NaOH (w/v) are
in the range of 0.1% to about 20%, in particular 0.5% to
11%, and more particular, 7%.
The solubilization step at 4° C. (i.e., digestion) of the
particularized ECM can extend over a period of time ranging
from a few minutes to several hours (e.g., 30 minutes to 48
hours) or days (e.g., 3-7 days), 30 minutes to 12 hours, 12-24
hours, 24 to 36 hours, 36 to 48 hours, or two to seven days.
In an embodiment of the invention, it is contemplated that
the time period required for the digestion step is determined
by the size of the particularized extracellular matrix material
and/or the concentration of the metal hydroxide used for
solubilization. For example, if the concentration of an alka-
line compound, such as NaOH, is low, longer incubation,
i.e., longer time period for solubilization may be required.
After the solubilization step in a basic solution, the solubi-
lized ECM (i.e., the gel form) is neutralized to a neutral pH
using molar concentrations, e.g., equimolar concentrations
of an acid in a volume sufficient for the solubilized ECM to
reach pH 6.8 to 7.4. Acids, which aid in neutralization of the
ECM gel, can be selected from weak or strong acids,
Selectivity of acids for the neutralization step depends on the
salts which are produced when an acids reacts with the basic
environment during neutralization. The resulting salt should
_►,
be biocompatible. For example, in an embodiment of the
invention, hydrochloric acid (HCl) is used to neutralize the
basic environment created by the base NaOH because the
resulting salt (i.e., NaCI) is clinically acceptable.
5 Following neutralization, optionally, gels can be sub-
jected to various dwell periods, 1-48 hours, 12-36 hours, or
36 to 48 hours to promote refolding of denatured bioactive
components. Dwell periods are generally performed with or
without shaking or stirring the gel in a cold room (i.e., at
10 temperature of about 4° C.), alternatively at room tempera-
ture. Dwell periods could extend beyond 48 hours to a few
days, for example, 3-7 days to promote restructuring of the
gel.
According to the method of the invention, once the gel is
15 neutralized it may optionally be subjected to one or more
steps of freeze drying cycles to facilitate the conversion of
the neutralized gel to a powder (having a neutral pH). The
powder can be reconstituted into a gel without altering its
bioactivity by mixing the powder with a liquid, such as
20 water, or a buffer solution which maintains the neutral of the
gel. In addition, preservation of bioactivity of ECMs may be
achieved through lyophilization.
In one embodiment according to the invention, the freeze
dried, solubilized ECM is reconstituted using water and two
25 3 mL syringes. One syringe contains the lyophilized gel, the
other water, and they are mixed together via a connecter
between the two syringes. The mixture is injected back and
forth several times to achieve mixing. Various concentra-
tions of ECM in NaOH can be tested for handling properties
30 (i.e. injectability, tackiness, viscosity) to determine their
ability to be applied using the two syringe system. The final
consistency of all gels is foam-like, and each one adheres to
the surface to which it is applied while also maintaining
consistency, which may be desirable in zero gravity condi-
35 tions, for example, in space. Accordingly, the gel invention
may be used for tissue repair during space exploration.
In one embodiment, to the solubilized and neutralized
ECM gel, particularized ECM is added to increase the
viscosity or the bioactivity of the gel. For example, UBM
40 powder in the size range of about 1 micron 1000 microns,
about 200-700 microns, about 300-600 microns, about 100
to 400 microns, about 200 microns or about 400 microns is
added to a UBM gel prepared by the above methods to
enhance the viscosity or the bioactivity of the gel, that is, the
45 gel has better handling or the gel is made capable of
producing a higher concentration of bioactive molecules, for
example, growth factors, such as FGF, e.g., FGF-2, CTGF,
or VEGF, ECM powder can be added, prior to, during, or
after the gels are neutralized.
50 In a particular embodiment, 7.0% UBM to 100 mM
NaOH solubilized at 4° C. is used to manufacture the
bioactive gel. A dwell period may or may not be used. UBM
powder may be added to the gel to increase viscosity and/or
bioactivity.
55
EXEMPLIFICATIONS
For the following exemplifications, any number of ECM
products such as but not limited to one or more of isolated
60 urinary bladder submucosa, small intestinal submucosa,
dermis, for example, could be used. In the following exem-
plifications, UBM, an ECM isolated from the urinary blad-
der and having epithelial basement membrane is used as an
exemplary ECM, However the invention disclosed herein is
65 not limited to UBM and is applicable to any isolated ECM.
In an exemplification, gels were created using various
concentrations of particularized UBM (0.5-11% w/v) solu-
US 9,795,713 B2
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bilized in various concentrations of NaOH (0.1-LOM).
UBM was solubilized for various time periods (1-48 hours)
in its respective concentration of UBM and NaOH at 4° C.,
In order to test whether the UBM could restructure after
solubilization, gels were also made using various dwell
periods (1-48 hours) following neutralization.
UBM gels created in the above manner were tested in
vitro for bioactive molecular content. In this study, growth
factor (e.g., FGF-2, CTGF, VEGF) content was analyzed.
Data for FGF-2 and VEGF content following solubilization
for each gel structure is shown in FIGS. 1 and 2. Lower
concentration gels (1-6%) are not shown but produced
similar results. As shown in FIGS. 1 and 2, FGF-2 and
VEGF, particularly VEGF levels increased in those studies.
In one study it was found that using 7.0% w/v UBM to
various range of NaOH with 24 hours of solubilizing at 4°
C. and no dwell period had significantly influenced the
FGF-2 and VEGF contents in the gel. FGF-2 and VEGF
contents were measure by standard ELISA procedures.
What is claimed is:
1. A method for increasing a growth factor content in a
bioactive wound healing material, comprising:
(a) providing a particularized extracellular matrix mate-
rial (ECM);
(b) solubilizing said particularized ECM from step (a) in
about 0.1% (w/v) to about 20% (w/v) of a base at a
concentration ranging between about O.1M to about
LOM;
(c) neutralizing the solubilized ECM from step (b); and
(d) gelling the neutralized ECM from step (c) at room
temperature, and, optionally
(e) subjecting the gelled ECM of step (d) to a dwell period
from 1-48 hours.
6
2. The method of claim 1 wherein said growth factor
comprises FGF-2.
3. The method of claim 1 wherein said growth factor
comprises CTGF.
s 4. The method of claim 1 wherein said growth factor
comprises VEGF.
5. The method of claim 1 wherein said growth factor
comprises FGF.
6. The method of claim 1 wherein the particularized ECM
io is in size range of about 1 micron-1000 microns.
7. The method of claim 1 wherein the particularized ECM
is in size range of about 200-700 microns.
8. The method of claim 1 wherein the particularized ECM
is in size range of about 300-600 microns.
15 9. The method of claim 1 wherein the particularized ECM
is in size range of about 100-400 microns.
10. The method of claim 1 wherein the particularized
ECM is in size range of about 200-400 microns.
11. The method of claim 1 wherein said ECM is urinary
20 bladder submucosa (UBS).
12. The method of claim 1 wherein said ECM is liver
basement membrane (LBM).
13. The method of claim 1 wherein said ECM is porcine
dermis (PD).
25 14. The method of claim 1 wherein said ECM is urinary
bladder matrix (UBM).
15. The method of claim 1 wherein the said particularized
ECM is solubilized in a solution.
16. The method of claim 15 wherein the solution com-
30 prises water.
17. The method of claim 15 wherein the solution com-
prises a buffer.
